Levera DT 250 Tablet contains Levetiracetam 250 mg, an antiepileptic agent indicated for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in adults and pediatric patients. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure propagation. Levera DT 250 is formulated as a dispersible tablet, facilitating ease of administration, particularly in patients with swallowing difficulties. The medication is typically prescribed as adjunctive therapy but may also be used as monotherapy depending on clinical judgment. Dosage should be individualized based on patient age, renal function, and seizure type, with gradual titration recommended to minimize adverse effects. Common side effects include somnolence, dizziness, headache, and fatigue, while serious adverse reactions such as behavioral changes or hypersensitivity are rare but warrant immediate medical attention. Levera DT 250 is contraindicated in patients with known hypersensitivity to Levetiracetam or any excipients. Caution is advised in patients with renal impairment, and dose adjustments may be necessary. This medication should be used under strict medical supervision, with regular monitoring to ensure optimal therapeutic outcomes and minimize potential risks.